Biotech - Drug Development
Biotechnology companies developing novel therapeutics across disease areas (excluding oncology-focused)
Rare Disease Therapeutics151
Neuroscience & CNS92
Immunology & Autoimmune79
Metabolic & Cardiometabolic42
Infectious Disease & Vaccines51
Clinical-Stage Platforms149
 LLY | Eli Lilly & Co. | Metabolic & Cardiometabolic | $1.0t | $1187.53 | +0.9% | 8.4K |
 JNJ | Johnson & Johnson | Immunology & Autoimmune | $0.6t | $261.57 | +0.0% | 8.8K |
 ABBV | ABBVIE INC. | Immunology & Autoimmune | $464.4b | $277.74 | +0.6% | 3.4K |
 MRK | Merck & Co., Inc. | Infectious Disease & Vaccines | $356.0b | $145.98 | +0.4% | 16.1K |
 AZN | AstraZeneca PLC | Metabolic & Cardiometabolic | $243.3b | $159.43 | +0.2% | 6.3K |
 TMO | Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $242.1b | $658.52 | 0.0% | 273 |
 AMGN | Amgen Inc | Rare Disease TherapeuticsImmunology & Autoimmune | $217.9b | $417.38 | 0.0% | 1.7K |
 GILD | Gilead Sciences Inc | Infectious Disease & Vaccines | $179.5b | $151.50 | 0.0% | 1.7K |
 PFE | Pfizer Inc. | Infectious Disease & Vaccines | $158.5b | $28.41 | +0.5% | 122.4K |
 VRTX | Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $127.9b | $513.80 | 0.0% | 715 |
 BMY | Bristol-Myers Squibb Co. | Immunology & Autoimmune | $124.9b | $61.08 | +3.7% | 685.2K |
 MRNA | Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $75.9b | $224.22 | 0.0% | 329.2K |
 REGN | Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $75.7b | $747.45 | 0.0% | 103 |
 A | Agilent Technologies Inc. | Clinical-Stage Platforms | $47.3b | $171.62 | -0.3% | 1.6K |
 IQV | IQVIA Holdings Inc. | Clinical-Stage Platforms | $42.5b | $261.00 | 0.0% | 881 |
 WAT | Waters Corp | Clinical-Stage Platforms | $41.8b | $434.00 | 0.0% | 36 |
 BIIB | Biogen Inc. Common Stock | Neuroscience & CNS | $32.5b | $233.52 | 0.0% | 20.7K |
 ALNY | Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $29.4b | $234.00 | 0.0% | 268 |
 ROIV | Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $25.8b | $34.63 | 0.0% | 7.4K |
 WST | West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $25.7b | $363.56 | 0.0% | 70 |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $25.5b | $57.22 | 0.0% | 3 |
 INSM | Insmed, Inc. | Rare Disease Therapeutics | $24.3b | $99.94 | 0.0% | 9.0K |
 INCY | Incyte Genomics Inc | Rare Disease Therapeutics | $23.4b | $112.06 | 0.0% | 160 |
 UTHR | United Therapeutics Corp | Rare Disease Therapeutics | $23.2b | $551.16 | 0.0% | 2.5K |
 RVTY | Revvity, Inc. | Clinical-Stage Platforms | $16.9b | $153.49 | +0.1% | 2.1K |
 MEDP | Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $16.7b | $609.42 | 0.0% | 42 |
 JAZZ | Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $15.3b | $219.30 | 0.0% | 414 |
 ASND | Ascendis Pharma A/S Ordinary Share | Clinical-Stage Platforms | $15.0b | $229.13 | 0.0% | 7 |
 NBIX | Neurocrine Biosciences Inc | Neuroscience & CNS | $14.6b | $142.25 | 0.0% | 71 |
 CRL | Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $13.9b | $303.05 | 0.0% | 96 |
 SMMT | Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $13.4b | $17.55 | 0.0% | 51.2K |
 BBIO | BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $13.1b | $66.16 | 0.0% | 637 |
 CORT | Corcept Therapeutics Inc. | Rare Disease Therapeutics | $12.6b | $120.90 | 0.0% | 631 |
 TWST | Twist Bioscience Corporation Common Stock | Clinical-Stage Platforms | $12.5b | $158.03 | 0.0% | 34.7K |
 ICLR | Icon Plc | Clinical-Stage Platforms | $12.5b | $164.13 | 0.0% | 1 |
 HALO | Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $12.5b | $110.78 | 0.0% | 3.2K |
 MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $11.5b | $472.31 | 0.0% | N/A |
 TECH | Bio-Techne Corp. | Clinical-Stage Platforms | $11.4b | $72.29 | 0.0% | 5 |
 BMRN | BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $11.1b | $55.70 | 0.0% | 10.6K |
 IBRX | ImmunityBio, Inc. Common Stock | Immunology & Autoimmune | $10.9b | $10.55 | 0.0% | 52.4K |
 AVTR | Avantor, Inc. | Clinical-Stage Platforms | $10.4b | $15.67 | +0.5% | 13.8K |
 RGEN | Repligen Corp | Clinical-Stage Platforms | $10.3b | $174.75 | 0.0% | 4.8K |
 APGE | Apogee Therapeutics, Inc. Common Stock | Immunology & Autoimmune | $10.2b | $135.09 | 0.0% | N/A |
 BRKR | Bruker Corporation | Clinical-Stage Platforms | $9.6b | $58.91 | 0.0% | 474 |
 KRYS | Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $9.5b | $330.74 | 0.0% | 54 |
 AXSM | Axsome Therapeutics, Inc | Neuroscience & CNS | $9.4b | $170.01 | 0.0% | 1.4K |
 QGEN | QIAGEN N.V. | Clinical-Stage Platforms | $9.2b | $45.67 | +0.7% | 1.8K |
 CYTK | Cytokinetics Inc. | Neuroscience & CNSRare Disease Therapeutics | $9.1b | $63.13 | 0.0% | 3.7K |
 ARWR | Arrowhead Research Corporation | Rare Disease Therapeutics | $9.1b | $63.16 | 0.0% | 843 |
 PTGX | Protagonist Therapeutics, Inc | Immunology & AutoimmuneMetabolic & Cardiometabolic | $9.1b | $144.00 | 0.0% | 2.6K |